142665-13-2

Basic information

• Product Name: 5,6-DiaMino-3-propylpyriMidine-2,4(1H,3H)-dione
• Synonyms: 5,6-DiaMino-3-propylpyriMidine-2,4(1H,3H)-dione;3-Propyl-5,6-diaminouracil
• CAS NO: 142665-13-2
• Molecular Formula: C₇H₁₂N₄O₂
• Molecular Weight: 184.19578
• Mol File: 142665-13-2.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Density: 1.269±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 11.59±0.40(Predicted)
• CAS DataBase Reference: 5,6-DiaMino-3-propylpyriMidine-2,4(1H,3H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6-DiaMino-3-propylpyriMidine-2,4(1H,3H)-dione(142665-13-2)
• EPA Substance Registry System: 5,6-DiaMino-3-propylpyriMidine-2,4(1H,3H)-dione(142665-13-2)

Safety Data

• Hazardous Substances Data: 142665-13-2(Hazardous Substances Data)

Usage

General Description

5,6-Diamino-3-propylpyrimidine-2,4(1H,3H)-dione is a chemical compound that belongs to the class of pyrimidine derivatives. It is a white to off-white crystalline powder that is primarily used in the pharmaceutical industry as an intermediate in the synthesis of various drugs such as antiviral and antineoplastic agents. 5,6-DiaMino-3-propylpyriMidine-2,4(1H,3H)-dione has shown potential in inhibiting the growth of cancer cells and possesses antiviral activity against certain viruses. Its structure and properties make it a valuable building block for the development of new pharmaceutical drugs. Additionally, it is also used as a research reagent in biochemical and medical studies to investigate its potential therapeutic applications and mechanisms of action. Overall, 5,6-Diamino-3-propylpyrimidine-2,4(1H,3H)-dione is an important compound with potential therapeutic benefits in the treatment of various diseases.

Upstream product

• 110472-90-7 6-amino-3-propyluracil 
• 146830-67-3 6-amino-5-nitroso-3-propyluracil 

Downstream Products

• 104285-82-7 1-Propylxanthine 
• 152529-70-9 Cyclopentane carboxylic acid (6-amino-2,4-dioxo-3-propyl-1,2,3,4-tetra hydro-pyrimidin-5-yl)-amide 
• 152529-72-1 6-amino-3-propyl-5-(4-sulfophenyl)carboxamidouracil 
• 174519-00-7 6-amino-5-(3-chlorocinnamoylamino)-3-propyluracil 
• 666715-99-7 6-amino-3-propyl-5-[4-[[p-nitrophenoxy]sulfonyl]benzamido]uracil 
• 666715-95-3 6-amino-3-propyl-5-[4-[[m-nitrophenoxy]sulfonyl]benzamido]uracil 
• 524944-76-1 9-cyclopentanecarboxamido-6,8-dioxo-7-propyl-1,3,4,6,7,8-hexahydro-2H-pyrimido[1,6-a]pyrimidine 
• 492439-38-0 7-benzyl-1-propylxanthine 
• 492439-40-4 7-benzyl-2-chloro-1-propylxanthine 
• 492439-36-8 6-amino-5-(benzylamino)-3-propyluracil 
• 492439-45-9 3-benzyl-5-propyl-7,8-dihydro-3H,5H-1,3,5,6,8a-pentaaza-as-indacen-4-one 
• 492439-73-3 3-benzyl-5-propyl-5,7,8,9-tetrahydro-3H-1,3,5,6,9a-pentaaza-cyclopenta[a]naphthalen-4-one 
• 492439-44-8 7-benzyl-2-(2-hydroxyethylamino)-1-propylpurin-6-one 
• 492439-72-2 7-benzyl-2-(3-hydroxypropylamino)-1-propylpurin-6-one 

Relevant articles and documents

Fluorescent-Labeled Selective Adenosine A2B Receptor Antagonist Enables Competition Binding Assay by Flow Cytometry

Fluorescent ligands represent powerful tools for biological studies and are considered attractive alternatives to radioligands. In this study, we developed fluorescent antagonists for A2B adenosine receptors (A2BARs), which are targeted by antiasthmatic xanthines and were proposed as novel targets in immuno-oncology. Our approach was to merge a small borondipyrromethene (BODIPY) derivative with the pharmacophore of 8-substituted xanthine derivatives. On the basis of the design, synthesis, and evaluation of model compounds, several fluorescent ligands were synthesized. Compound 29 (PSB-12105), which displayed high affinity for human, rat, and mouse A2BARs (Ki = 0.2-2 nM) and high selectivity for this AR subtype, was selected for further studies. A homology model of the human A2BAR was generated, and docking studies were performed. Moreover, 29 allowed us to establish a homogeneous receptor-ligand binding assay using flow cytometry. These compounds constitute the first potent, selective fluorescent A2BAR ligands and are anticipated to be useful for a variety of applications.

Selective, high affinity A2B adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

A series of N-1 monosubstituted 8-pyrazolyl xanthines have been synthesized and evaluated for their affinity for the adenosine receptors (AdoRs). We have discovered two compounds 18 (CVT-7124) and 28 (CVT-6694) that display good affinity for the A2B AdoR (Ki = 6 nM and 7 nM, respectively) and greater selectivity for the human A1, A2A, and A3 AdoRs (>1000-, >830-, and >1500-fold; >850-, >700-, and >1280-fold, respectively). CVT-6694 has been shown to block the release of interleukin-6 and monocyte chemotactic protein-1 from bronchial smooth muscle cells (BSMC), a process believed to be promoted by activation of A2B AdoR.

Method of wound healing using A2B adenosine receptor antagonists

The present invention relates to methods of wound healing using A2B adenosine receptor antagonists. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.